Insulin (Aspart Insulin [Novolog], Regular Insulin)
Pre-clinicalCompleted 0 views this week 0 watching💤 Quiet
Interest: 26/100
26
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Diabetic Ketoacidosis
Conditions
Diabetic Ketoacidosis
Trial Timeline
Jan 1, 2005 → Dec 1, 2007
NCT ID
NCT00920725About Insulin (Aspart Insulin [Novolog], Regular Insulin)
Insulin (Aspart Insulin [Novolog], Regular Insulin) is a pre-clinical stage product being developed by Novo Nordisk for Diabetic Ketoacidosis. The current trial status is completed. This product is registered under clinical trial identifier NCT00920725. Target conditions include Diabetic Ketoacidosis.
What happened to similar drugs?
20 of 20 similar drugs in Diabetic Ketoacidosis were approved
Approved (20) Terminated (3) Active (0)
Hype Score Breakdown
Clinical
3
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00920725 | Pre-clinical | Completed |
Competing Products
20 competing products in Diabetic Ketoacidosis